No Flush Niacin (Inositol Hexanicotinate) 800 mg
Product analysis
No Flush Niacin (Inositol Hexanicotinate) 800 mg provides a clearly identified niacin preparation at a low cost per serving. The available cardiovascular evidence does not support this preparation for the blood markers considered.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality53
Niacin is clearly identified as inositol hexanicotinate. The quality of the additional inositol-related declarations cannot be confirmed more closely.
Ingredient Transparency88
All listed amounts are disclosed and the niacin preparation is identified. One additional inositol-related form remains unspecified.
Value For Money100
The niacin serving offers good value in the available price comparison. Low cost does not establish usefulness for its intended cardiovascular purpose.
Customer Satisfaction88
Customer feedback is very positive across thousands of ratings. The large review base gives an established picture of satisfaction.
Product Focus0
The available cardiovascular evidence does not support this niacin preparation for the markers considered. The other listed inositol-related ingredients do not establish an additional cardiovascular benefit.
- Format
Capsule - Container
- 100 Capsule(s)
- Per serving
- $0.15
- Customer rating
- 4.7 · 3,746 ratings
Goals
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Niacin (Inositol Hexanicotinate) | 640 mg | |
Inositol Hexanicotinate | 800 mg | |
Inositol (Inositol Hexanicotinate) | 160 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability57
Niacin Form & Goal Alignment
Precursor Source Quality
Dose, Safety & Label Transparency75
Clarity of Chemical Form
Form-Specific Dosage Efficacy
Flush Risk & Safety Labeling
Value100
Price Per Effective Serving
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.